- Home
- Equipment
- australasia
- potential ad therapeutic
Show results for
Refine by
Potential Ad Therapeutic Equipment Supplied In Australasia
5 equipment items found
by:AdAlta Limited based inBundoora, AUSTRALIA
An i-body is a human protein that belongs to the class of next generation antibodies. The i-body is built on the scaffold of a human protein and engineered with two loops that mimic the shape of shark antibodies. These loops are responsible for binding or interacting with a particular target (in circulation or on a cell) that is causing disease. i-bodies are identified and developed using our ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...
by:Microba Life Sciences based inBrisbane City, AUSTRALIA
Developing novel therapeutics from the human microbiome; The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity. Microba has established a platform for drug discovery and development that leverages a growing, proprietary Databank of human microbiome samples and associated metadata. Precision techniques enable ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. Following further development, AdAlta ...
Manufactured by:NeuroScientific Biopharmaceuticals Ltd. based inCottesloe, AUSTRALIA
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt neurodegeneration. We believe that EmtinB has potential to bridge this gap and bring this breakthrough medicine to clinics, bringing new hope to ...